TAT meetings are unique oncology phase 1 meetings run by the world’s leaders in early-phase clinical development of cancer therapeutics. Educational introductions of target biology will help young oncologists and "newcomers" understand the science behind new agents. TAT meetings are characterized by an open, academic atmosphere and a highly interactive setting giving academic clinical investigators, research scientists and industry clinical development professionals to interact effectively and discuss topics of common interest.

NEW IN TAT 2013
Several new features will be added to the TAT concept in 2013 to increase its value for oncologists, investigators and scientists who are in the early stages of their career. The organizers are also planning to create interesting opportunities for smaller biotech companies to present and discuss their leads.  Watch our further announcements in the months ahead!

IMPORTANT DATES
The scientific program is currently under development; the first version will be released in August 2012.
Abstract submission will open in August; submission deadline end 2012
Registration will open in August.